RFL | Rafael Holdings, Inc. Stock Overview

(Stock Exchange: NYSE)

Day's Range	1.6000 - 1.6800
52 Week Range	1.2900 - 2.2700
Beta	0.37
Implied Volatility	251.26%
IV Rank	71.45%
Day's Volume	17,313
Average Volume	24,769
Shares Outstanding	23,921,900
Market Cap	38,992,697
Sector	Real Estate
Industry	Real Estate - Services
IPO Date	2018-03-27

Valuation
Profitability
Growth
Health
P/E Ratio	-1.36
Forward P/E Ratio	N/A
EPS	-1.20
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	13
Country	USA
Website	RFL

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

RFL's peers: DUO, IRS, MAYS, RMR, NEN, KW, CBRE, RMAX, DBRG, RDFN, JLL, CWK, CIGI, CSGP, NMRK, HOUS, OPEN, DOMA

*Chart delayed

Analyzing fundamentals for RFL we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see RFL Fundamentals page.

Watching at RFL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on RFL Technicals page.